Modulation of peroxisome proliferation-activated receptors

A technology of compounds and modulators, applied in the field of DNA vectors, can solve the problems of limited therapeutic efficacy and side effects of PPAR

Inactive Publication Date: 2007-02-21
ABGENOMICS COOPERATIEF U A
View PDF14 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, most PPAR treatments have limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Modulation of peroxisome proliferation-activated receptors
  • Modulation of peroxisome proliferation-activated receptors
  • Modulation of peroxisome proliferation-activated receptors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 3

[0163] Example 3 PGR3 / ZADH2 Small Molecule Inhibitors

[0164]The recombinant human PGR3 / ZADH2 protein was expressed and its enzyme activity was detected. Similar to murine PGR3 / ZADH2, recombinant human PGR3 / ZADH2 has 15-ketoprostaglandin-Δ 13 - Reductase activity and catalyzes the conversion of 15-ketoprostaglandins to 13,14-dihydro-15-ketoprostaglandins.

[0165] The inhibitory effect of compounds 1-49 on PGR3 / ZADH2 activity was tested. These compounds are available commercially (eg, from Sigma-Aldrich, St. Louis, MO) or can be prepared from methods well known in the art. Inhibition assays were performed as described above. Different concentrations of PGR3 / ZADH2 inhibitors were added to the reaction mixture and incubated at 37°C for 2 hours.

[0166] More specifically, 50 μM of compounds 8, 12, 13, and 27, and 25 μM of trifluorobenzyl-2-hydroxycinnamic acid (compound 22) were added to the PGR3 / ZADH2 enzyme reaction system, and the enzymatic reduction of 15-ketoprostatic ...

Embodiment 4

[0170] Effect of Example 4 PGR3 / ZADH2 Inhibitor on Insulin Sensitivity

[0171] The effect of two of the aforementioned PGR3 / ZADH2 inhibitors, compounds 12 and 28, on insulin sensitivity was examined as follows. 3T3-L1 cells were induced to differentiate in the same manner as above. According to the method described by Finga et al. (Endocrinology 134:728-735), by measuring the response to 2-deoxy-D-[ 3 H] Glucose uptake was performed in a glucose transport assay. 1.67M inhibitor or 45nMPPAR-γ agonist, Avandia, was added to the cells.

[0172] 10M Cytochalasin B was used to measure background levels of glucose uptake. 100 nM insulin was used to stimulate glucose uptake. Insulin treatment alone increases glucose uptake by more than 10-fold in differentiated 3T3-L1 cells. Glucose uptake was increased 30-fold in the presence of any two PGR3 / ZADH2 inhibitors. The ability of these inhibitors to increase glucose uptake was found to be comparable to that of AVANDIA.

[0173] Th...

Embodiment 5

[0176] Example 5 RNA interference

[0177] Silencing of PGR3 / ZADH2 expression by RNA interference in 3T3-L1 preadipocytes. To generate vectors encoding interfering RNAs targeting PGR3 / ZADH2, standard methods were used to synthesize vectors containing 5'-GAT CCG TGC CAC GTT ATC GGA ACC TTC AAG AGA GGT TCC GAT AAC GTGGCA CTT TTT TGG AAA-3' (SEQ ID NO: 9; forward primer) and oligonucleotides of AGC TTT TCC AAA AAAGTG CCA CGT TAT CGG AAC CTC TCT TGA AGG TTC CGA TAA CGT GGC ACG-3' (SEQ ID NO: 10; reverse primer). They were then annealed and introduced into the linear siRNA expression vector, pSilencer™ neo (catalog # 5764, Ambion). The siRNA expression vector was then introduced into 3T3-L1 preadipocytes by electroporation. Stable transfected clones were isolated using G418 selection. PGR3 / ZADH2 mRNA levels in these claims were then detected using standard RT-PCR. It was found that PGR3 / ZADH2 mRNA transcript levels were suppressed.

[0178] The clones described above were used...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Method of treating diseases associated with peroxisome proliferator-activated receptors by administering to a subject in need thereof an effective amount of 15-ketoprostaglandin-delta 13 - Reductase modulators. Also disclosed is a method of identifying a compound that inhibits the reductase activity, and a method of lowering blood glucose levels by administering to a subject an effective amount of the reductase inhibitor.

Description

[0001] Cross References to Related Applications [0002] Pursuant to 35 U.S.C. §119(e), this application claims priority to U.S. Provisional Application Serial No. 60 / 707,897, filed August 12, 2005, the entire contents of which are hereby incorporated by reference. Background technique [0003] Peroxisome proliferator-activated receptors (PPARs) belong to a family of nuclear receptors that regulate fat and glucose metabolism. Three mammalian PPARs have been identified, namely PPAR-α, PPAR-γ and PPAR-Δ. Activation by dietary fatty acids or their metabolic derivatives, PPARs can initiate transcriptional temporal cascades that result in altered fat and glucose metabolism. For example, through activation, PPAR-γ, which is highly expressed in adipose tissue, promotes glucose uptake and lowers blood glucose levels. [0004] Based on their role in fat and glucose metabolism, PPARs are predicted to be therapeutic targets in diseases such as type II diabetes, obesity, dyslipidemia, c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N9/02C07K14/435C12N15/53C12N15/12C07K16/40A61K38/44A61K38/17A61K48/00A61K39/395A61P3/10A61P3/04A61P3/06A61P9/00A61P35/00
CPCC07K14/70567C12N9/0004C12N9/0006A61K31/33A61P29/00A61P3/00A61P3/04A61P35/00A61P3/06A61P9/00A61P9/10A61P3/10C07K14/705
Inventor 林荣华庄立民
Owner ABGENOMICS COOPERATIEF U A
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap